CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...License Agreement • June 5th, 2020 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • New York
THIS LICENSE AGREEMENT (“Agreement”) is made effective as of the 19th day of December, 2016 (the “Effective Date”), by and between Fusion Pharmaceuticals Inc., a Canadian corporation with a place of business at 1280 Main Street West, NRB-A316, Hamilton, Ontario, Canada L8S 4Kl (“Licensee”) and ImmunoGen, Inc., a Massachusetts corporation with offices at 830 Winter Street, Waltham, MA 02451-1477, USA (“ImmunoGen”). Licensee and ImmunoGen may, from time-to-time, be individually referred to as a “Party” and collectively referred to as the “Parties”.
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...License Agreement • June 5th, 2020 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • Ontario
This AGREEMENT dated as of February 22, 2017 is made by and between Fusion Pharmaceuticals Inc. a Canadian corporation, having its principal place of business at NRB-A316, 1280 Main St West, Hamilton, ON. L8S 4K1 (“Fusion”) and the Centre for Probe Development and Commercialization Inc., a Canadian corporation, having its principal place of business at NRB-A316, 1280 Main St West, Hamilton, ON L8S 4K1 (“CPDC”).
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...Master Service Agreement • June 5th, 2020 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • Ontario
This Master Service Agreement (the “Agreement”), effective as of February 22, 2017 (the “Effective Date”), is established between Centre for Probe Development and Commercialization, a not-for-profit research and services institution with offices located at McMaster University, Nuclear Research Building, 1280 Main Street West, Hamilton, Ontario, Canada, L8S 4K1, (“CPDC”), and Fusion Pharmaceuticals Inc. (“FUSION”), having a place of business at Nuclear Research Building, 1280 Main Street West, Hamilton, Ontario, Canada, L8S 4K1, to define the general conditions to govern any contracted services to be undertaken for FUSION by CPDC. In this Agreement, FUSION and CPDC may be referred to individually each as “Party” or collectively as the “Parties.”
TWO INTERNATIONAL PLACE Boston, Massachusetts OFFICE LEASE FUSION PHARMACEUTICALS US INC.Office Lease • June 5th, 2020 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances)
Agreement dated October 1,2019, between Fort Hill Square 2 Owner LLC, a Delaware limited liability company (“Landlord”), and Fusion Pharmaceuticals US Inc., a Delaware corporation (“Tenant”).
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...Supply Agreement • June 5th, 2020 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances)
This Supply Agreement is conducted under the general provisions of the Master Services Agreement and the Quality Agreement entered into between the PARTIES. Unless explicitly stated within this Supply Agreement should there be discrepancies between the Supply Agreement and the Master Services Agreement, then the Master Services Agreement will be the controlling document.
FUSION PHARMACEUTICALS INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • June 5th, 2020 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • New York
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (the “Agreement”) is made and entered into as of March 25, 2019, by and among Fusion Pharmaceuticals Inc., a corporation existing under the Canada Business Corporations Act (the “Company”), Fusion Pharmaceuticals (Ireland) Limited, a private company limited by shares governed by the laws of the Republic of Ireland and a subsidiary of the Company (the “Fusion Ireland”), those certain holders of the Company’s Class A Preferred Shares (the “Class A Preferred Shares”) and Class B Preferred Shares (the “Class B Preferred Shares” and, together with the Class A Preferred Shares, the “Class Preferred Shares”) listed on Schedule A (the “Class Preferred Shareholders”) and those certain holders of the Company’s Class A Special Voting Shares (the “Class A Special Voting Shares”) and Class B Special Voting Shares (the “Class B Special Voting Shares” and, together with the Class A Special Voting Shares, the “Special Voting Shares”) listed on Sche
ASSET PURCHASE AGREEMENT by and among FUSION PHARMACEUTICALS INC. and RAINIER THERAPEUTICS, INC. and FORTIS ADVISORS LLC, as SELLER REPRESENTATIVE Dated as of March 10, 2020Asset Purchase Agreement • June 5th, 2020 • Fusion Pharmaceuticals Inc. • Biological products, (no disgnostic substances) • Delaware
Each of the Milestone Payments shall be payable one (1) time only. For the avoidance of doubt, (x) each of the Milestone Payments shall become payable upon the occurrence of the associated Milestone Event, irrespective of the order in which the Milestone Events occur relative to each other, and (y) no amounts shall be due for subsequent or repeated achievements by a Product of any Milestone Event. If Purchaser skips a milestone event listed in the above Sections 1.05(i)(A)-(B) or 1.05(ii)(A)-(B), then Purchaser shall pay the amounts set forth in the skipped milestone upon achieving a subsequent milestone event, in addition to the amounts payable for such subsequent milestone event. In accordance with the foregoing, the maximum
